Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  NASDAQ OMX COPENHAGEN  >  Zealand Pharma Aktieselskabet    ZEAL   DK0060257814

ZEALAND PHARMA AKTIESELSKABET (ZEAL)
Mes dernières consult.
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq Omx Copenhagen
07/16/2018 07/17/2018 07/18/2018 07/19/2018 07/20/2018 Date
99.2(c) 100.8(c) 98.4(c) 98.9(c) 97.9(c) Last
235 271 90 077 90 429 60 476 75 091 Volume
+2.27% +1.61% -2.38% +0.51% -1.01% Change
More quotes
Financials (DKK)
Sales 2018 109 M
EBIT 2018 -342 M
Net income 2018 -341 M
Finance 2018 129 M
Yield 2018 -
Sales 2019 334 M
EBIT 2019 -189 M
Net income 2019 -254 M
Debt 2019 31,3 M
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales2018 26,8x
EV / Sales2019 9,19x
Capitalization 3 041 M
More Financials
Company
Zealand Pharma A/S is a biotechnology company that engages in the discovery, design, and development of peptide based medicines.Its products include Soliqua and Lyxumia.The company was founded by Lars Hellerung Christiansen and Bjarne Due Larsen on October 19, 1998 and is headquartered in Glostrup,... 
More about the company
Surperformance© ratings of Zealand Pharma Aktieselska
Trading Rating : Investor Rating :
More Ratings
Latest news on ZEALAND PHARMA AKTIESELSKA
07/20Silence Therapeutics Appoints David Horn Solomon as Chief Executive Officer
AQ
07/11ZEALAND PHARMA MAJOR SHAREHOLDER ANN : Van Herk Investments
AQ
06/27ZEALAND PHARMA AKTIESELSKABET : presents two dasiglucagon milestone studies at t..
AQ
06/27ZEALAND PHARMA AKTIESELSKABET : - Survey demonstrating underuse of glucagon resc..
AQ
06/12ZEALAND PHARMA AKTIESELSKABET : achieves milestone in first Phase 3 trial with d..
AQ
06/09ZEALAND PHARMA AKTIESELSKABET : achieves milestone in first Phase 3 trial with d..
AQ
06/08ZEALAND PHARMA AKTIESELSKABET : achieves milestone in first Phase 3 trial with d..
AQ
05/29ZEALAND PHARMA AKTIESELSKABET : reports completion of the second and pivotal Pha..
AQ
05/28ZEALAND PHARMA AKTIESELSKABET : grants new warrants under employee warrant progr..
AQ
05/28ZEALAND PHARMA AKTIESELSKABET : reports completion of the second and pivotal Pha..
AQ
More news
Sector news : Bio Therapeutic Drugs
07/19Novartis, MorphoSys and Galapagos Shares Rise on News of Deal
DJ
07/09LONZA : restates 2017 figures after changing accounting standard
RE
07/03Sanofi beefs up diabetes pipeline to retrieve success
RE
06/29European stocks shrug off trade worries with quarterly gain
RE
06/29GILEAD SCIENCES : Rival Novartis, Gilead CAR-T therapies win European panel reco..
RE
More sector news : Bio Therapeutic Drugs
Latest Tweets
06/28#GSMA's Andrew Parker shares details on exciting #IoT experiences at #MWCS18 
06/26’s Andrew Parker shares details on experiences attendees can expect at cove.. 
06/25 will feature focused zones, demonstrations, events and more. 's Andrew Park..
2
06/14#GSMA’s Andrew Parker shares details on #IoT experiences attendees can expect..
1
06/12’s Andrew Parker shares details about highlights in the industry. Experience..
2
More tweets
Qtime:56
News from SeekingAlpha
06/08Zealand Pharma's dasiglucagon successful in late-stage study 
05/17Zealand Pharma A/S 2018 Q1 - Results - Earnings Call Slides 
05/16Zealand Pharma's (ZLDPF) CEO Britt Meelby Jensen on Q1 2018 Results - Earning.. 
05/16Zealand Pharma reports Q1 results 
03/20Zealand Pharma's dasiglucagon successful in late-stage hypoglycemia study 
Chart ZEALAND PHARMA AKTIESELSKA
Duration : Period :
Zealand Pharma Aktieselska Technical Analysis Chart | ZEAL | DK0060257814 | 4-Traders
Technical analysis trends ZEALAND PHARMA AKTIESELSKA
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 9
Average target price 145  DKK
Spread / Average Target 48%
EPS Revisions
Managers
NameTitle
Britt Meelby Jensen President & Chief Executive Officer
Alf Gunnar Martin Nicklasson Chairman
Ivan Møller Senior VP-Technical Development & Operations
Mats Blom Chief Financial Officer & Executive Vice President
Adam Steensberg Chief Medical Officer & Senior Vice President
Sector and Competitors
1st jan.Capitalization (M$)
ZEALAND PHARMA AKTIESELSKABET16.35%478
GILEAD SCIENCES8.00%100 185
VERTEX PHARMACEUTICALS18.38%45 900
REGENERON PHARMACEUTICALS-2.35%38 962
GENMAB9.33%10 874
NEUROCRINE BIOSCIENCES, INC.33.30%9 332